Back to Search
Start Over
Allergenicity and immunogenicity of the major mugwort pollen allergen Art v 1 chemically modified by acetylation
- Source :
- Clinical and Experimental Allergy
- Publication Year :
- 2009
-
Abstract
- Treating allergies with modified allergens is an approach to make the treatment safer and more efficient. Art v 1 is the most prominent allergen of mugwort pollen and a significant cause of hayfever around Europe. The aim of this study was to reduce the allergenicity of Art v 1 by acetylation, and to investigate the capacity of the modified protein to generate blocking antibodies. The reduction of allergenicity of Art v 1 following acetylation was monitored by immunoblot, ELISA inhibition using a pool of sera from mugwort pollen allergic patients, basophil activation assay and by skin prick testing of mugwort-allergic patients. Rabbits were immunized against Art v 1 and acetylated Art v 1 (acArt v 1) and the rabbit antisera were tested for their capacity to block human IgE binding in ELISA. Human T cell proliferation against Art v 1 and acArt v 1 was examined in peripheral blood mononuclear cells (PBMCs) of mugwort pollen allergic patients and cytokine release in PBMC cultures was monitored. Acetylation of Art v 1 gave a derivative of reduced allergenicity in the in vitro and ex vivo tests applied. The skin test reactivity to acArt v 1 was significantly reduced in 19 patients when compared with the reactivity to Art v 1. Rabbit antibodies to acArt v 1 and Art v 1 showed similar capacity to block human IgE binding to Art v 1 in inhibition ELISA. Both proteins were able to induce proliferation of PBMCs and CD3/CD4(+) cells of mugwort-allergic patients. Release of IL-5 was significantly reduced in cultures stimulated with acArt v 1. Art v 1 modified by acetylation had a significantly reduced allergenicity in vitro and in vivo, while its immunogenicity was retained. Modification of allergens by acetylation could be a new strategy for allergen-specific immunotherapy. Cite this as: I. Perovic, M. Milovanovic, D. Stanic, L. Burazer, D. Petrovic, N. Milcic-Matic, G. Gafvelin, M. van Hage, R. Jankov and T. Cirkovic Velickovic, Clinical and Experimental Allergy, 2009 (39) 435-446.
- Subjects :
- Male
Allergy
medicine.disease_cause
Antigen-Antibody Reactions
0302 clinical medicine
Allergen
mugwort pollen allergy
Immunology and Allergy
Plant Proteins
0303 health sciences
biology
Immunogenicity
allergen-specific immunotherapy
Acetylation
Middle Aged
3. Good health
Basophils
Allergoid
Cytokines
Pollen
Female
Rabbits
Antibody
Adult
Art v 1
Adolescent
Immunology
Basophil Degranulation Test
Binding, Competitive
03 medical and health sciences
Young Adult
Antigen
medicine
Hypersensitivity
Animals
Humans
Isoelectric Point
acetylation
030304 developmental biology
Artemisia vulgaris
business.industry
Allergens
Antigens, Plant
Immunoglobulin E
biology.organism_classification
medicine.disease
Molecular Weight
Basophil activation
blocking antibodies
Immunoglobulin G
Antibody Formation
biology.protein
Leukocytes, Mononuclear
allergoid
Immunization
business
030215 immunology
Subjects
Details
- ISSN :
- 13652222
- Volume :
- 39
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
- Accession number :
- edsair.doi.dedup.....f1b0c6e05c1e8e157a046f993fe2f0df